Positive decision for Idogen’s orphan designation application in Europe
The European Medicines Agency's Committee for Orphan Medicinal Products (COMP) has reached a positive decision regarding Idogen’s application for orphan drug designation in Europe. This means that the COMP has made the assessment that the application meets all the necessary criteria and they will therefore recommend that the European Commission grants Idogen a formal orphan drug designation.An orphan drug designation provides several important benefits for Idogen. A product that is classified as an orphan drug receives market exclusivity in the EU for ten years following marketing